We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+0.58%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$602M
AUM Growth
-$78.7M
Cap. Flow
-$49.8M
Cap. Flow %
-8.27%
Top 10 Hldgs %
57.8%
Holding
63
New
5
Increased
16
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$12.7M
2
LRMR icon
Larimar Therapeutics
LRMR
+$8.22M
3
WGS icon
GeneDx Holdings
WGS
+$4.86M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$4.59M
5
KROS icon
Keros Therapeutics
KROS
+$4.2M

Top Sells

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$12.1M
2
IRON icon
Disc Medicine
IRON
+$11M
3
CKPT
Checkpoint Therapeutics
CKPT
+$9.19M
4
IMVT icon
Immunovant
IMVT
+$7.49M
5
SMTI icon
Sanara MedTech
SMTI
+$7.01M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
26
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.52M 1.25%
205,381
-16,619
-7% -$643K
LRMR icon
27
Larimar Therapeutics
LRMR
$421M
$7.15M 1.19%
+727,800
New +$8.22M
TELA icon
28
TELA Bio
TELA
$29.2M
$7.1M 1.18%
440,465
+75,465
+21% +$1.03M
MCRB icon
29
Seres Therapeutics
MCRB
$49.7M
$5.96M 0.99%
12,500
-2,500
-17% -$1.05M
SIOX
30
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.26M 0.87%
2,000,000
– –
WGS icon
31
GeneDx Holdings
WGS
$2.66B
$5.24M 0.87%
+11,328
New +$4.86M
AVTX icon
32
Avalo Therapeutics
AVTX
$1.08B
$5.13M 0.85%
544
-359
-40% -$3.01M
LITS
33
Lite Strategy Inc
LITS
$34M
$4.46M 0.74%
78,250
+450
+0.6% +$28.9K
AVEO
34
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.26M 0.71%
647,000
-188,000
-23% -$1.3M
FMTX
35
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$4.26M 0.71%
+171,000
New +$4.59M
LUMO
36
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.82M 0.63%
382,000
+5,100
+1% +$56.8K
OPTN
37
DELISTED
OptiNose
OPTN
$3.81M 0.63%
81,773
+26,706
+48% +$1.36M
KZR
38
DELISTED
Kezar Life Sciences
KZR
$3.79M 0.63%
69,780
-1,340
-2% -$76.1K
CRNX icon
39
Crinetics Pharmaceuticals
CRNX
$9B
$3.78M 0.63%
200,500
+12,500
+7% +$220K
APTO
40
DELISTED
Aptose Biosciences, Inc.
APTO
$3.25M 0.54%
2,178
+241
+12% +$525K
SRRA
41
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.22M 0.54%
165,500
+14,361
+10% +$261K
CRDF icon
42
Cardiff Oncology
CRDF
$76.7M
$3.08M 0.51%
463,000
-113,000
-20% -$958K
VIRX
43
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.92M 0.48%
257,189
+153,589
+148% +$1.54M
PHVS icon
44
Pharvaris
PHVS
$2.6B
$1.49M 0.25%
+79,837
New +$1.81M
CYPH
45
Cypherpunk Technologies Inc
CYPH
$204M
$886K 0.15%
54,000
+15,190
+39% +$256K
CFRX
46
DELISTED
ContraFect Corporation
CFRX
$255K 0.04%
724
-2,326
-76% -$761K
CDTX
47
DELISTED
Cidara Therapeutics
CDTX
$148K 0.02%
+3,668
New +$155K
BLRX
48
BioLineRX
BLRX
$12.1M
$47K 0.01%
417
– –
AUTL
49
Autolus Therapeutics
AUTL
$628M
– –
-2,112,918
Closed -$12.1M
CKPT
50
DELISTED
Checkpoint Therapeutics
CKPT
– –
-292,596
Closed -$9.19M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2021 Portfolio in Review

As of Q2 2021, Opaleye Management held 63 positions worth $602M, down 12% from $681M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Opaleye Management withdrew a net $49.8M in Q2 2021, closing 15 positions and reducing 14 holdings. Its most notable exit was Autolus Therapeutics, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Opaleye Management opened a new position in Larimar Therapeutics worth $7.15M.

  • Opaleye Management's largest Q2 2021 buy was Larimar Therapeutics: 727,800 shares worth $7.15M.
  • Opaleye Management added most to Kiniksa Pharmaceuticals in Q2 2021, an estimated $12.7M increase.
  • Opaleye Management's biggest Q2 2021 reduction was BridgeBio Pharma, cutting an estimated $3.8M.
  • Opaleye Management fully exited Autolus Therapeutics in Q2 2021, selling an estimated $12.1M.
  • Opaleye Management's ten largest holdings make up 58% of its $602M portfolio in Q2 2021.
  • Opaleye Management opened 5 new positions and closed 15 in Q2 2021.
  • Opaleye Management's portfolio value fell 12% quarter-over-quarter to $602M.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.